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Abstract 28
29
The balance between vasoconstrictor/sodium retaining and vasodilator/natriuretic systems is 30
essential for maintaining body fluid and electrolyte homeostasis. Natriuretic peptides, such as 31
atrial natriuretic protein (ANP) belong to the vasodilator/natriuretic system. ANP is produced 32
by the conversion of pro-ANP into ANP which is achieved by a proteolytical cleavage 33
executed by corin. In the kidney, ANP binds to the natriuretic peptide receptor-A (NPR-A)34
and enhances its guanylyl cyclase activity, thereby increasing intracellular cyclic guanosine 35
monophosphate production to promote natriuretic and renoprotective responses. In the 36
glomerulus, ANP increases glomerular permeability and filtration rate and antagonizes the 37
deleterious effects of the renin-angiotensin-aldosterone system activation. Along the 38
nephron, natriuretic and diuretic actions of ANP are mediated by inhibiting the basolaterally 39
expressed Na+/K+-ATPase, reducing apical sodium, potassium and protein organic cation 40
transporter in the proximal tubule, and decreasing the Na+-K+-2Cl- co-transporter activity and41
the renal concentration efficiency in the thick ascending limb. In the medullary collecting duct,42
ANP reduces sodium reabsorption by inhibiting the cyclic nucleotide gated cation channels, 43
the epithelial sodium channel, and the heteromeric channel transient receptor potential-44
vanilloid 4 and -polycystin 2 and diminishes vasopressin-induced water reabsorption. Long 45
term ANP treatment may lead to NPR-A desensitization and ANP-resistance, resulting in 46
augmented sodium and water reabsorption. In mice, corin deficiency impairs sodium 47
excretion and causes salt-sensitive hypertension. Characteristics of ANP resistance and 48
corin deficiency are also encountered in patients with edema-associated diseases,49
highlighting the importance of ANP-signalling in salt-water balance and renal 50
pathophysiology.51
52
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1. Introduction55
56
Maintaining body fluid and electrolyte homeostasis is a fundamental requirement in virtually 57
all animals. The regulation is controlled by a variety of endocrine, autocrine and neuronal 58
factors, which can be divided into two antagonizing systems: the vasoconstrictor/sodium 59
retaining systems, such as the renin-angiotensin-aldosterone system (RAAS), the60
sympathetic nervous system, endothelin-1 and antidiuretic hormones; and the 61
vasodilator/natriuretic systems, such as the natriuretic peptides and nitric oxide (NO) (94). 62
63
The natriuretic peptides were evolved in the earliest vertebrates to serve as osmoregulatory 64
hormones (105, 106). In mammals, the natriuretic peptide system is well preserved. Three 65
similar peptides, i.e. atrial, brain or B-type and C-type natriuretic peptides (ANP, BNP and 66
CNP, respectively) have been identified. Among them, ANP and BNP are more closely 67
related, as indicated by high sequence similarities and a shared receptor, natriuretic peptide 68
receptor-A (NPR-A), also called guanylyl cyclase-A. ANP is produced mainly in atrial and 69
ventricular myocytes, and secreted in response to cardiac wall stretching and various stimuli 70
such as endothelins and alpha-adrenergic factors (29). BNP is generated mostly in cardiac 71
ventricles and released in response to volume or pressure overload (48). The function of 72
CNP differs from that of ANP and BNP. CNP is widely expressed in the central nervous 73
system, the vasculature, and the bones, where it acts in a paracrine fashion by binding to a 74
separate receptor, the natriuretic peptide receptor-B (NPR-B) to regulate cell differentiation 75
and organ function (31, 78, 84). All three natriuretic peptides indiscriminately bind to a third 76
receptor, NPR-C, which serves as the clearance receptor for these peptides (37). 77
78
Like many peptide hormones, the natriuretic peptides are synthesized in precursors, i.e. pro-79
forms. Proteolytic cleavage to remove the pro-peptide is an essential step to activate the 80
natriuretic peptides. In cardiomyocytes, where most ANP and BNP are produced, the 81
membrane-bound serine protease corin has been identified as a critical enzyme for activating 82
the natriuretic peptides (118). Corin, however, is not involved in pro-CNP processing. It has 83
been shown that pro-CNP processing is mostly mediated by furin, an intracellular proprotein 84
convertase (114). 85
86
2. Corin structure and function 87
Corin is a trypsin-like serine protease (116). The protein contains a single-span 88
transmembrane domain at the N-terminus, which anchors corin on the cell surface. Among89
normal tissues, corin is most abundantly expressed in cardiomyocytes (117). Functional 90
studies have shown that corin is critical for activating the natriuretic peptides and regulating 91
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salt-water balance and blood pressure (6, 116). In mice, for example, lack of corin leads to 92
salt-sensitive hypertension (20, 111), a phenotype similar to that in ANP knockout mice (59). 93
To date, corin gene variations and mutations have been reported in patients with 94
hypertension and heart disease, supporting the physiological importance of corin in 95
maintaining normal blood pressure and cardiac function (35, 38, 93, 124). Most recent 96
studies also indicate a local function of corin and ANP in the pregnant uterus to promote 97
spiral artery remodelling and to prevent pregnancy-induced hypertension (26). Interestingly, 98
corin mutations that impair the natriuretic peptide processing activity have been identified in99
patients with preeclampsia supporting a role for corin in preeclampsia–induced symptoms100
(26). 101
102
3. ANP receptors and downstream signalling103
NPR-A/NPR-B and NPR-C are two major types of receptors for the natriuretic peptides.104
NPR-A and NPR-B are membrane guanylyl cyclase receptors, whereas NPR-C lacks the 105
guanylyl cyclase activity (70). The binding of ANP to the receptor NPR-A leads to the 106
conversion of guanosine triphosphate (GTP) to the intracellular second messenger cyclic 107
guanosine monophosphate (cGMP) (55, 90). The active NPR-A receptor is a homodimer.  108
Each NPR-A monomer contains an extracellular ANP-binding domain at its amino-terminus109
and an intracellular guanylyl cyclase domain at its carboxyl terminus (47). Synthetized 110
cGMPs bind to target proteins, including the cGMP-dependent protein kinases (PKG) I and II, 111
cyclic-nucleotide gated ion-channels, and the cyclic nucleotide phosphodiesterase (11). 112
113
Two different subtypes of NPR-C with molecular masses of 67 and 77 kDa, respectively, 114
have been identified.  These receptors may bind to a broad range of ligands, including ANP, 115
BNP and CNP. 4-23C-ANP is a cleaved form of ANP, which also binds to NPR-C, but not 116
NPR-A or NPR-B. The 77-kDa NPR-C primarily serves as a clearance receptor for ligand 117
internalization, whereas the 67-kDa NPR-C also participates in adenylyl cyclase activity 118
inhibition through inhibitory guanine nucleotide regulatory protein Gi and activation of 119
phospholipase C to exert anti-hypertensive effects (70). 120
121
Recently, both NPR-A and NPR-C were shown to mediate the effects of ANP by enhancing 122
the Ca2+/calmodulin-dependent NO synthase (NOS) activity, another factor of the123
vasodilator/natriuretic system with similar renal effects as ANP. It appears that these 124
receptors may act through different mechanisms; NPR-A-induced NO production was shown 125
to be cGMP-dependent, whereas NPR-C-dependent NO release was partially mediated by 126
Gi protein (41, 42). 127
128
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4. Renal expression of ANP-signalling cascade components and its functional 129
implications 130
Within the kidney, components of the ANP signalling cascade are widely expressed and 131
antagonize the vasoconstrictor/sodium retaining system by affecting the activity and 132
expression of various transporters, channels and other signalling components (Figure 1).133
134
4.1. Glomerulus 135
Within the glomerulus, corin expression was undetectable (43), suggesting that glomerular 136
ANP production and activation are negligible, if any. ANP from the circulation, however, may 137
act on glomerular epithelial and mesangial cells (21, 66). The receptor NPR-A has been 138
localized to the surface of podocytes and mesangial cells (82, 103). Attributed renal actions 139
of ANP include the regulation of the glomerular filtration rate (GFR) and glomerular140
permeability. ANP-induced increases in GFR and filtration fractions have been reported in141
numerous studies [for review see (52)]. This function has been suggested to occur by raising 142
the capillary glomerular pressure through relaxation of the afferent arteriole and contraction 143
of the efferent arteriole (40). ANP was also shown to cause a rapid (within 5 min) increase in 144
glomerular permeability (7). Analysis of the glomerular filtration barrier revealed that ANP 145
directly and in a reversible manner increases the radius and the number of large glomerular 146
pores without affecting the charge selectivity. As a result of the augmented glomerular 147
permeability, ANP may induce microalbuminuria, which is associated with many diseases 148
such as diabetes and congestive heart failure (CHF) (7, 125). 149
150
The ANP-induced cGMP production and its functional consequence are not fully understood. 151
It may involve reorganization of F-actin filaments, thereby causing cellular relaxation (101). 152
The possible function of podocytes in this process remains to be elucidated. Mesangial cells 153
express NPR-A and respond to ANP with strong elevations in intracellular cGMP (10). ANP 154
may also relax mesangial cells by increased hyperpolarisation, leading to an increase in 155
ultrafiltration coefficient associated with augmented glomerular hydrostatic pressure, GFR 156
and filtration fraction (52). 157
158
Additionally, the endogenous ANP/NPR-A/cGMP system may have pleiotropic and 159
renoprotective properties (82) by antagonizing the RAAS. Ogawa et al. (82) demonstrated 160
that an aldosterone-induced glomerular injury led to more severe proteinuria and fibrotic 161
changes in NPR-A knockout mice than control wild-type mice. The authors proposed that 162
ANP-induced NPR-A activation may inhibit local extracellular signal-regulated kinase and163
p38 mitogen-activated protein kinase signalling pathways as well as the formation of reactive 164
oxygen species. Another possible mechanism underlying the aldosterone-antagonizing165
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effects of ANP was reported recently. In transfected human embryonic kidney cells, ANP 166
attenuated the aldosterone-induced nuclear translocation of the mineralocorticoid receptor167
(MR) via NPR-A/cGMP-dependent PKGI, resulting in an association of NPR-A with the MR 168
and thus preventing MR activation (75). Furthermore, the importance of the balance between 169
the RAAS and the ANP systems is demonstrated by an Ang-(1-9)-induced ANP secretion 170
from cardiomyocyte in an AT2-receptor-dependent manner involving phosphoinositide kinase 171
3, Akt, NO, and cGMP (19). Thus, the balance between the RAAS and the ANP-induced 172
signalling cascade may be regulated through receptor interactions, hormone secretion and 173
intracellular signalling pathways. 174
175
4.2. Proximal tubule 176
In the proximal tubule, corin was localized to the apical membrane of the endocytic 177
apparatus and in the brush border membrane (BBM) of rodent kidneys (89) as well as in 178
human kidneys (43). The particular corin expression pattern suggests the cleavage of filtered 179
and locally produced pro-ANP into active ANP. In this nephron segment, local production of 180
ANP mRNA was detected by in situ hybridization (67, 89). Natriuresis elicited by ANP has 181
been attributed to the inhibition of sodium reabsorption at both proximal (122) and distal 182
nephron segments including the collecting duct. ANP may promote natriuresis without 183
altering GFR (96). Lithium clearance studies showed that ANP inhibited proximal tubular 184
sodium reabsorption (17, 50), in part by counteracting angiotensin-stimulated sodium 185
reabsorption (51). ANP also inhibits several Na+-dependent transport systems, such as the 186
Na+/H+-exchanger (112) and type IIa Na/Pi co-transporter (8). The Na+/K+-ATPase plays a 187
pivotal role in sodium reabsorption in all tubular segments including the proximal tubule. It 188
has been shown that the Na+/K+-ATPase is an ANP target (4, 15) and that the inhibition of 189
the Na+/K+-ATPase by ANP is mediated, to a large extent, via renal dopamine 1-like 190
receptors. Among other transports that may be regulated by ANP include protein organic 191
cation transporter and Cl- and K+ channels (28, 53, 54, 76). 192
193
4.3. Distal tubule 194
Within the distal tubule, corin is highly expressed in vesicles near the apical plasma 195
membrane of medullary thick ascending limb (89), where it is believed to cleave locally 196
produced pro-ANP (67, 89). Cytochemical localization revealed a plasma membrane 197
expression of NPR-A in the thick ascending limb upon ANP treatment (92). In this nephron 198
segment, ANP was shown to inhibit Cl--transport in a cGMP- and PKG-dependent manner (9,199
80). Furthermore, increased intracellular cGMP levels were shown to directly inhibit Na+-K+-200
2Cl- co-transporter (NKCC2) activity (85, 86) by decreasing its apical surface expression 201
through a mechanism mediated by cGMP-stimulated phosphodiesterase 2 (PDE2) (5). 202
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Presumably, this effect may affect NKCC2 trafficking by PDE2-mediated reduction in cAMP203
and subsequently protein kinase A levels. Thus, ANP may inhibit NKCC2 and reduce urine 204
concentrating capacity, thereby increasing urine excretion. It also has been shown that ANP 205
may initiate Ca2+ transients in isolated cortical thick ascending limbs. This activity appeared 206
to be mediated by NPR-C (27). ANP-dependent NPR-C activation is known to activate 207
phospholipase C and release NO. The functional implication in ANP-mediated NO release 208
remains to be determined. 209
210
4.4. Collecting duct211
In the collecting duct system, corin was identified within the apical plasma membrane and 212
apical vesicles (89). The signal intensity increased towards the medulla. Like in the nephron 213
segments, local ANP mRNA and protein expression was detected. Moreover, all components 214
of the ANP-induced signalling cascade could be identified within the inner medullary 215
collecting duct (IMCD). Immunohistochemical studies localized NPR-A to the apical 216
membranes of IMCD (45), and the cGMP-stimulated phosphodiesterase 5 (PDE5) and 217
protein kinase G II (PKGII) in the cytosol (89, 104). 218
219
It is well established that the medullary collecting duct is the main site of ANP action in 220
promoting sodium excretion (122). The current data indicate that ANP regulates Na+221
reabsorption at both the apical and basolateral sides in IMCD. As in the nephron segments, 222
sodium reabsorption in principal cells of the IMCD consists of passive Na+ entry through the 223
apical membrane and active pumping into the peritubular space by the basolateral Na+,K+-224
ATPase. The epithelial sodium channel (ENaC) is the main sodium channel for sodium entry 225
and is characterized by low conductance (4-5 pS) with high specificity for Na+ over K+ (>20 226
fold), which is inhibited by amiloride (18, 102). 227
228
Current data on cGMP/PKGII-induced ENaC activation are less conclusive. In single-patch 229
clamp studies with Xenopus 2F3 cells, ANP and 8-pCPT-cGMP were shown to decrease the 230
open probability of ENaC in an NPR-A-dependent manner (49). Long term ANP treatment,231
however, induced a translocation of ENaC into the apical membrane presumably to prevent232
sustained natriuresis after prolonged ANP exposure (110). 233
234
In addition to ENaC, another type of sodium channel exists in principal cells of the collecting 235
duct, i.e. the cyclic nucleotide gated cation channels (CNG) (24, 71, 72). CNG channels have 236
a higher conductance (28 pS), transport Na+, K+ and NH4+ with similar affinities, and are 237
inhibited by cGMP, amiloride and diltiazem (24, 71, 72). It has been shown that cGMP 238
inhibits these channels by PKG-dependent channel phosphorylation and allosteric changes239
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(71). It is possible, therefore, that CNGs may serve as another ANP target in promoting240
sodium excretion (Figure 2).241
242
At the basolateral site of IMCD, ANP is known to inhibit Na+/K+-ATPase activity through 243
PKGII-induced phosphorylation and in a cGMP-dependent manner (Figure 2) (15, 44, 98). 244
Moreover, ANP was shown to modulate transepithelial water transport in collecting duct cells. 245
In isolated rat and rabbit CCD, short term ANP treatment reduces vasopressin-stimulated 246
water permeability (33, 79). Furthermore, in vasopressin-pre-treated cells ANP markedly 247
decreased the kinetics of cell swelling, which was mimicked by 8-bromo-cGMP and blunted 248
by PKGII inhibition. ANP also reduced vasopressin-induced phosphorylation of aquaporin-2 249
(AQP2) at position S256 (64). However, in untreated collecting duct cells, long-term ANP 250
treatment induced an AQP2 translocation into the apical membrane followed by increased 251
phosphorylation, which may increase transepithelial water flux (14, 110). Thus, similarly as 252
shown for ENaC, prolonged ANP actions favour volume retention.  253
254
Another mechanism of ANP-dependent natriuresis has been proposed recently and may 255
involve the inhibition of flow-activated Ca2+ entry into collecting duct cells (Figure 2) (39). The256
transient receptor potential vanilloid 4 (TRPV4) and the transient receptor potential polycystin 257
2 (TRPP2) were shown to form a heteromeric channel complex in cilia, a crucial structure for 258
flow sensation. It was found that ANP, cGMP and PKGII inhibited Ca2+ entry through their 259
action on heteromeric TRPV4-P2 channels. PKGII was shown to phosphorylate the channel 260
complex on TRPP2T719A and TRPP2S827A, thereby inhibiting the channel complex formation 261
and preventing the flow-induced Ca2+ entry in to CCD cells. These findings are intriguing. 262
Further studies are needed to elucidate the influence of intracellular Ca2+ levels on sodium 263
absorption.264
265
5. Regulation of ANP-cascade components266
ANP, corin and NPR-A expression pattern are mainly regulated by varying their transcription 267
rate. The involved transcription factors as well as factors modulating their action have been 268
identified in the past years. 269
GATA transcription factor family members, particularly GATA-4 and -6, and T box factor 5,270
have been shown to play an important role for ANP gene expression in cardiac myocytes. 271
GATA-4 functionally synergizes with transcription factors GATA-6, MEF-2, dHAND, SRF, 272
Nkx2.5 and YY1 (48). The phosphorylation of GATA-4 by p38 mitogen-activated protein 273
kinase (MAPK) was shown to increase the binding affinity of GATA-4 to the ANP promoter,274
thereby promoting ANP gene expression (48). Other factors modulating ANP gene 275
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expression include D-adrenergic agonists, endothelin, prostaglandin F2D, growth factors, 276
vitamin D, retinoids, glucocorticoids, mechanical strain, and hypoxia (48). 277
278
In the corin gene promoter, similar conserved binding sites for Tbx5, GATA, Nkx2.5 and 279
Krüppel-like transcription factors have been identified (34). GATA-4 appears to be the major 280
transcription factor in the heart accounting for increased corin and ANP gene expression281
under hypertrophic conditions (115). Transcription factors controlling renal corin and ANP 282
expression pattern as well as factors modulating the promoter activity in the kidney remain to 283
be determined.284
285
The NPR-A gene expression is regulated primarily by Sp1 possessing three binding sites in286
the promoter region, as determined by mutational analysis (48). A number of factors have 287
been reported to regulate the NPR-A gene promoter activity, which includes vitamin D, 288
angiotensin II, endothelin, osmotic stimuli, endothelial NOS, p38 MAPK (48) and serum and 289
glucocorticoid inducible kinase 1 (23). Interestingly, ANP was demonstrated to negatively 290
regulate NPR-A promoter activity and gene expression via a cGMP-dependent mechanism291
involving cGMP-response element-binding protein (CREBP) (74). CREBP is widely 292
distributed in human tissues with high abundance in the heart and was found at low levels in 293
the kidney. 294
295
Phosphorylation is another important mechanism in regulating NPR-A activity (99, 120). 296
Binding of ANP to NPR-A induces a homologous desensitization of NPR-A which correlates 297
with a complex phosphorylation pattern of the receptor. Under steady state conditions, NPR-298
A is highly phosphorylated at multiple sites on its intracellular domain including Ser473,299
Ser487, Ser497, Thr500, Thr502, Thr506, Ser510 and Thr513. ANP-provoked 300
desensitization was accompanied with increased phosphorylation at Ser487, whereas at the 301
other sites dephosphorylation occurred. Performing functional analysis of Ser487 using site-302
directed mutagenesis revealed that phosphorylation at this site blunts the NPR-A activation 303
but also prevents further desensitization (99, 119). It is believed that ANP-mediated NPR-A-304
desensitization is one of the reasons for the receptor resistance in the presence of high 305
circulating ANP levels.306
307
6. Mechanisms in ANP Resistance308
In many edematous disease states, ANP-induced signalling components may be improperly 309
regulated and thereby prevent the natriuretic action of ANP. In fact, the ANP resistance is a 310
hallmark of diseases such as CHF (22), liver cirrhosis (68, 77), and nephrotic syndrome (87,311
107, 108), which are commonly associated with sodium retention. In these diseases, 312
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cumulative sodium retention often leads to edema and ascites. As an underlying mechanism 313
a maladaptive renal response to compensate edematous disorders has been identified and 314
reduced ANP response and a dysregulated ANP-induced signaling was found (25, 65, 81,315
91, 95).  316
317
In animal models of and patients with CHF, liver cirrhosis and proteinuric kidney disease, 318
attenuated or reduced urine flow rate and decreased urinary sodium excretion are common 319
(12, 22, 30, 32, 46, 57, 58, 61, 69, 73, 113). Increased circulating ANP levels often correlated 320
with the severity of the disease (16, 68, 87, 100). Under these pathological conditions, the321
renal response to pharmacological ANP infusion was markedly attenuated (22, 83, 87, 88,322
107). In fact, the lack of a proper renal response to ANP is a pathological feature, but the 323
underlying mechanism remains controversially discussed. It has been suggested that the 324
ANP resistance may be due to decreased ANP availability and/or NPR-A desensitization at325
the renal site.326
327
To date, reduced uterine, cardiac and renal corin level and/or activity have been found in328
animal models of and patients with preeclampsia, heart failure and nephrotic syndrome (56,329
89, 109). These findings suggest that corin deficiency may impair the ANP signaling 330
pathway, contributing to the ANP resistance in these diseases. In addition, there is growing 331
evidence that PDE5 up-regulation may also play a role in the ANP resistance. PDE5 is 332
known to degrade cGMP. In chronic cardiovascular diseases, liver cirrhosis or nephrotic 333
syndrome, increased PDE5 levels have been associated with decreased renal cGMP levels, 334
which may contribute to ANP resistance and sodium retention in patients (1, 3, 87, 107). 335
  336
The renal origin of volume retention has been located in the collecting duct, which involves 337
increased activation of the Na+/K+-ATPase (2, 36, 73) and augmented expression and apical 338
membrane targeting of ENaC subunits (60, 61, 123). In liver cirrhosis, this increase was 339
shown to occur early in disease progression and was reduced subsequently, probably as a340
counter regulatory mechanism (62). It remains unclear whether Na+/K+/2Cl- and Na+/Cl- co-341
transporter contribute to volume retention under these disease conditions (60, 97, 121). 342
343
In rats, long-term ANP infusion induced AQP2 and ENaC trafficking into the apical 344
membrane (110). Similarly, ANP- and cGMP-stimulated mpkCCDcl14 cells led to increased 345
membrane insertion of AQP2 (13). It is possible that in edematous conditions with high 346
circulating ANP levels, the augmented membrane availability of ENaC and AQP2 may 347
promote sodium and water retention and may therefore, at least partially, be accountable for 348
the accompanied formation of edema and/or hypertension. 349
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350
Corin is the rate limiting enzyme for ANP activation. Recently, reduced corin levels were 351
found in kidneys of proteinuric rats (89) and patients with chronic kidney disease (43). So far,352
no data have been reported regarding the renal expression levels of the ANP-induced 353
signaling components in patients with or animal models of CHF, liver cirrhosis and354
preeclampsia. Analysis of kidneys from corin knockout mice revealed a paradoxical increase 355
of medullary PKGII, PDE5 and ENaC E-subunit, whereas ENaC D- and Jsubunits as well as 356
Na+/K+-ATPase expression levels remained unchanged (89). Corin knockout mice developed 357
salt-sensitive hypertension, which was caused by impaired sodium excretion and increased 358
water retention (111). This phenotype was corrected by amiloride treatment; treatment with 359
amlodipine, a Ca2+-channel inhibitor or losartan, an AT1-receptor blocker had no such effect.360
These data suggest a potential role of ENaC in inducing a salt-sensitive hypertension in corin 361
knockout mice. Similarly, kidneys of proteinuric rats had increased levels of PKGII and PDE5 362
in the medullary collecting duct (Figure 3). It remains unclear how corin reduction and/or the363
increase in PKGII and PDE5 lead to ENaC activation. Further studies are needed to364
elucidate the underlying molecular mechanism.365
366
Summary and perspectives367
Corin and ANP play an important role in regulating body fluid and electrolyte homeostasis. 368
Components of the ANP signaling cascade are expressed in the glomerulus and along the 369
nephron to exert natriuretic, diuretic and renoprotective effects. The main natriuretic and 370
diuretic ANP actions occur in the medullary collecting duct via its receptor NPR-A. 371
Dysregulation of the ANP-induced signaling cascade may impair sodium and water 372
excretion. In this context, reduced corin activity, as the rate limiting enzyme for ANP 373
production, and altered expression levels of ANP signaling components have been found in 374
animal models and patients with ANP resistance and sodium and water retention. There are 375
many open questions which need to be addressed in future. For example, what is the 376
importance of the renal vs. the cardiac corin-ANP system on renal ANP-induced natriuresis 377
and diuresis? What are the molecular mechanisms of long term ANP treatment leading to378
augmented ENaC and AQP2 membrane availability? How is the expression level of corin 379
and ANP signaling components in CHF, liver cirrhosis or preeclampsia? How is the time 380
course of expression level of corin and ANP-induced signaling components in edematous 381
diseases? How may dysregulated ANP signaling cascade components contribute to the ANP 382
resistance commonly observed in patients with edematous diseases? Further studies to 383
answer these questions will help understanding the role of corin and ANP in sodium 384
homeostasis and renal pathophysiology.385
386
387
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Figure legend 765
Figure 1. Distribution of ANP production and corin expression along the nephron. In766
renal epithelia ANP mRNA was encountered together with corin expression in the proximal 767
tubule, medullary thick ascending limb and medullary collecting duct (purple), suggesting an 768
immediate activation of pro-ANP and subsequent paracrine signalling. Additional ANP mRNA 769
without corin expression was found in podocytes, connecting tubule and cortical collecting 770
duct (red) where a downstream activation of the secreted pro-ANP is necessary.771
772
Figure 2. ANP-induced action in medullary collecting duct cells. Urinary ANP binds to its 773
receptor NPR-A and thereby induces the conversion of GTP to cGMP. cGMP inhibits apically 774
sodium entry through the cyclic nucleotide gated channels (CNG), heteromeric channel of 775
transient receptor potential V4 (TRPV4) and -P2 (TRPP2) and basolaterally through the 776
Na+/K+-ATPase (NKA) and thereby promoting natriuresis.777
778
Figure 3. Effects of reduced renal corin expression in nephrotic syndrome. Reduced 779
renal corin expression leads to increased pro-ANP and reduced ANP levels through 780
diminished pro-ANP processing. The decreased ANP levels result in reduced conversion of 781
guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). The782
downstream impact on the signaling cascade involves increased phosphodiesterase 5 783
(PDE5) and phospho-PDE5, increased protein kinase G II (PKGII) and increased expression 784
level of E-ENaC, which may lead to overall sodium and volume reabsorption/retention. This 785
figure is adapted from an illustration in a commentary by J. Klein (63). 786
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